PRKN and Alzheimer disease: Significantly decreased levels were detected when immunoprecipitated Beclin-1 was probed with parkin (Fig 1F, 28 ± 6.5, mean ± sd, p < 0.03, N = 5) and inversely when immunoprecipitated parkin was probed with Beclin-1 (46 ± 18, mean ± sd, N = 5), suggesting decreased parkin-Beclin-1 interaction in AD.